High-Value Federal Grants ($5M+) — August 01, 2026

Regeneron won a $695.7 million cost-plus-fixed-fee contract from HHS/BARDA under full-and-open competition, with a 10-year performance period through 2027. The cost-plus structure minimizes profit volatility and ensures cost recovery, providing a stable $69.6 million annual revenue stream with $238.8 million already outlaid.

AT&T's $261.1 million firm-fixed-price delivery order for telephone systems at foreign posts ended in March 2021, with only $27.3 million outlaid. This historical award provides no current or future revenue visibility for AT&T, making it a neutral data point with limited investment relevance.

Lockheed Martin's $39.95 million cost-plus-fixed-fee contract from NASA for advanced technology R&D ended in August 2020, with $17.3 million obligated. This sole-source award is a historical data point with no ongoing revenue, offering no forward-looking investment signal.

Regeneron's $695.7M BARDA contract has a vague description ('IGF::OT::IGF'), limiting visibility into specific program deliverables and milestones. Execution risk is elevated due to the 10-year duration and lack of clarity on R&D targets.

The digest is heavily concentrated on a single contract—Regeneron's $695.7M award represents 71.4% of total obligations. This concentration risk means investment conclusions are overly dependent on one company and one agency (HHS/BARDA).

The digest covers contracts awarded in 2014-2017, with two of three contracts already completed. The data is historical and may not reflect current budget priorities or continuing resolution risks for FY2026.

Regeneron's $695.7M BARDA contract aligns with sustained government investment in biodefense and pandemic preparedness, a bipartisan priority. The cost-plus structure and 10-year duration create a stable growth platform for Regeneron in the government biotech R&D space.

The Department of State's $261.1M telecommunications contract, though completed, signals sustained investment in diplomatic communications infrastructure. Follow-on contracts for modernized systems could benefit AT&T or competitors like Verizon.

Regeneron's $695.7M cost-plus-fixed-fee contract from BARDA demonstrates the government's commitment to long-term biodefense R&D, with a 10-year performance period providing predictable revenue. The cost-plus structure reduces contractor risk and ensures stable margins.

Two of three contracts (AT&T $261.1M, Lockheed Martin $17.3M) are completed awards with no current revenue contribution. Their inclusion dilutes the digest's actionable signals, underscoring the need to focus on active, ongoing contracts for investment decisions.

{"entity" => "Regeneron Pharmaceuticals", "reason" => "Holds the only active, high-value contract in the digest ($695.7M from BARDA) with a 10-year performance period through 2027. Future outlay amounts and contract modifications are key triggers.", "trigger" => "Option exercise announcements, BARDA budget increases, pandemic preparedness legislation"}

{"entity" => "AT&T", "reason" => "Completed $261.1M State Department contract may signal follow-on opportunities for telecommunications modernization at foreign posts.", "trigger" => "State Department re-compete for telecommunications services, modernization RFPs"}

{"entity" => "Lockheed Martin", "reason" => "Historical $17.3M NASA contract ended in 2020; watch for recompetition of advanced technology R&D work at NASA Ames Research Center.", "trigger" => "NASA R&D budget allocations, re-compete announcements for engineering services"}